Trevi Therapeutics TRVI
NASDAQ TRVI
$14.81 -0.10 (-0.64%)
At close: Nov 11, 2026 · 4:00 PM EST

Trevi Therapeutics (TRVI) Gains from Sales and Divestitures (2023)

Updated

Trevi Therapeutics' Gains from Sales and Divestitures came in at -$7,000 for FY2025.

Analysis

Trevi Therapeutics (TRVI) Gains from Sales and Divestitures (2023) Analysis & Trends

  • Per Business Quant, earlier years put Gains from Sales and Divestitures at -$10,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Trevi Therapeutics 2.13 Bn 1.15 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 -10,000.00
API Access

Trevi Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TRVI&period=max&api_key=YOUR_API_KEY